TABLE 2.
Descriptive characteristics of 180 participants at baseline1
| Magnesium treatment (n = 87) | Placebo (n = 93) | P | |
|---|---|---|---|
| Age, y | 60.4 ± 8.3 | 61.7 ± 8.3 | 0.302 |
| Male sex, % | 52 | 48 | 0.663 |
| BMI, kg/m2 | 29.4 ± 6.0 | 30.3 ± 6.5 | 0.302 |
| eGFR | 81.0 ± 14.0 | 78.0 ± 15.0 | 0.162 |
| TRPM7 genotype GG, % | 65 | 68 | 0.643 |
| Smoking status, % | 0.213 | ||
| Never | 46 | 59 | |
| Ever | 44 | 33 | |
| Current | 10 | 8 | |
| Drinking status, % | 0.253 | ||
| Never | 44 | 32 | |
| Ever | 17 | 20 | |
| Current | 39 | 48 | |
| Physically active ≥2 d/wk, % | 84 | 78 | 0.333 |
| Education less than college, % | 10 | 9 | 0.913 |
| White race, % | 98 | 99 | 0.523 |
| Family history of colorectal cancer, % | 14 | 11 | 0.533 |
| Daily nutrients intake, mg/d | |||
| Total calcium | 1327 ± 332 | 1236 ± 364 | 0.062 |
| Total magnesium | 366 ± 97 | 333 ± 96 | 0.012 |
| Calcium-to-magnesium intake ratio | 3.7 ± 0.9 | 3.9 ± 1.6 | 0.862 |
| Season, % | 0.823 | ||
| Spring | 16 | 20 | |
| Summer | 41 | 35 | |
| Fall | 26 | 27 | |
| Winter | 16 | 17 | |
| Aspirin use, % | 30 | 24 | 0.343 |
| NSAID use, % | 20 | 18 | 0.833 |
| Plasma 25(OH)D, ng/mL | 33.4 ± 10.2 | 32.0 ± 12.7 | 0.532 |
| Plasma 25(OH)D3, ng/mL | 32.3 ± 10.4 | 30.1 ± 11.3 | 0.202 |
| Plasma 25(OH)D2, ng/mL | 1.12 ± 2.31 | 2.84 ± 10.89 | 0.322 |
| Plasma 1,25(OH)2D3, pg/mL | 81.4 ± 50.9 | 84.2 ± 51.3 | 0.702 |
| Plasma 24,25(OH)2D3, ng/mL | 4.66 ± 3.71 | 3.82 ± 2.78 | 0.242 |
1Continuous variables are means ± SDs; categorical variables are percentages. eGFR, estimated glomerular filtration rate; NSAID, nonsteroidal anti-inflammatory drug; TRPM7, transient receptor potential cation channel, subfamily M, member 7; 1,25(OH)2D3, 1,25-dihydroxyvitamin D3; 24,25(OH)2D3, 24,25-dihydroxyvitamin D3; 25(OH)D, 25-hydroxyvitamin D; 25(OH)D2, 25-hydroxyvitamin D2; 25(OH)D3, 25-hydroxyvitamin D3.
2Wilcoxon test.
3Pearson chi-square test.